Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Pancragen cycle length: what human studies ran

Not approved — research use onlyBLimited human data
Short answer: there is no established Pancragen cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Pankragen forte was given for 4 weeks in the prediabetes study 15.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Pancragen combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Pancragen cycle length?
No. Human studies administered Pancragen for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Pancragen?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Pancragen dosing reference Full research page

References

  1. lysyl-glutamyl-aspartyl-tryptophanamide [Supplementary Concept] — entry terms Lys-Glu-Asp-Trp-NH2, KEDW-NH2, pancragen Medical Subject Headings, U.S. National Library of Medicine. 2026
  2. Prospects of using pancragen for correction of metabolic disorders in elderly people Bulletin of Experimental Biology and Medicine. 2011
  3. Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2015
  4. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2014
  5. Effects of pancragen on the differentiation of pancreatic cells during their ageing Bulletin of Experimental Biology and Medicine. 2013
  6. Peptides tissue-specifically stimulate cell differentiation during their aging Bulletin of Experimental Biology and Medicine. 2012
  7. Tetrapeptide stimulates functional activity of the pancreatic cells in aging (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2012
  8. Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide Bulletin of Experimental Biology and Medicine. 2010
  9. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus Bulletin of Experimental Biology and Medicine. 2007
  10. ClinicalTrials.gov registry query for "pancragen" (0 studies returned) ClinicalTrials.gov (U.S. National Library of Medicine). 2026
  11. openFDA Drug Label API query for "pancragen" (no approved human drug labeling for a peptide of this name) U.S. Food and Drug Administration / openFDA. 2026
  12. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. 2026
  13. World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026) World Anti-Doping Agency. 2026
  14. PubMed query for "pancragen" (9 records) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026
  15. [The tetrapeptide pankragen forte efficiency in elderly people with prediabetic state] Adv Gerontol. 2013